Publications by authors named "Martin Kropff"

Claim this Profile
O
One CGIAR and the Integrated Agri-food Systems Initiative: From short-termism to transformation of the world's food systems.
Bram Govaerts, Christine Negra, Tania Carolina Camacho Villa, Xiomara Chavez Suarez, Anabell Diaz Espinosa, Wietske Kropff, Martin Kropff

PLoS One· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Autologous-allogeneic autologous tandem stem cell transplantation and maintenance therapy with thalidomide for multiple myeloma patients under 60 years of age: a prospective, phase II study.
Nicolaus Kröger, Gerald Wulf, Ute Hegenbart, Andreas Burchert, Matthias Stelljes, Martin Kropff

Haematologica· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis.
Stefan Knop, Monika Engelhardt, Peter Liebisch, Christoph Meisner, Ernst Holler, Martin Kropff

Leukemia· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bortezomib consolidation following autologous transplant in younger and older patients with newly diagnosed multiple myeloma in two phase III trials.
Christian Straka, Stefan Knop, Martin Vogel, Jürgen Müller, Martin Kropff

Eur J Haematol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bortezomib and low-dose dexamethasone with or without continuous low-dose oral cyclophosphamide for primary refractory or relapsed multiple myeloma: a randomized phase III study.
Martin Kropff, Martin Vogel, Guido Bisping, Rudolf Schlag, Rudolf Weide

Ann Hematol· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial.
Hermann Einsele, Monika Engelhardt, Christoph Tapprich, Jürgen Müller, Peter Liebisch, Martin Kropff

Br J Haematol· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of High-Cut-Off Dialysis on Renal Recovery in Dialysis-Dependent Multiple Myeloma Patients: Results from a Case-Control Study.
Hans U Gerth, Michele Pohlen, Dennis Görlich, Gerold Thölking, Martin Kropff

PLoS One· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Autologous Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Drug Induction: A Retrospective Single-Center Analysis.
Gabriela B Thoennissen, Dennis Görlich, Ulrike Bacher, Thomas Aufenberg, Anne-Christin Hüsken, Martin H Kropff

Acta Haematol· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of maintenance therapy on subsequent treatment in patients with newly diagnosed multiple myeloma: use of "progression-free survival 2" as a clinical trial end-point.
Meletios A Dimopoulos, Maria T Petrucci, Robin Foà, John Catalano, Martin Kropff

Haematologica· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged ≥ 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial.
Meletios A Dimopoulos, Antonio Palumbo, Roman Hajek, Martin Kropff, Maria Teresa Petrucci

Leuk Lymphoma· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Therapeutic strategies in multiple myeloma: the future role of bendamustine].
Hartmut Goldschmidt, Martin Kropff, Lars-Olof Mügge, Wolfram Pönisch

Onkologie· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial.
Meletios A Dimopoulos, Michel Delforge, Roman Hájek, Martin Kropff, Maria T Petrucci

Haematologica· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.
Jesús F San Miguel, Rudolf Schlag, Nuriet K Khuageva, Meletios A Dimopoulos, Ofer Shpilberg, Martin Kropff

J Clin Oncol· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
POEMS syndrome treated with melphalan high-dose therapy and autologous blood stem cell transplantation: a single-institution experience.
Gabriela B Thoennissen, Nils H Thoennissen, Fleur Fritz, Andreas Hilbig, Andrea Kerkhoff, Martin Kropff

Ann Hematol· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial.
Martin Kropff, Honorata Giongco Baylon, Jens Hillengass, Tadeusz Robak, Roman Hajek

Haematologica· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Continuous lenalidomide treatment for newly diagnosed multiple myeloma.
Antonio Palumbo, Roman Hajek, Michel Delforge, Martin Kropff, Maria Teresa Petrucci

N Engl J Med· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiple myeloma treatment strategies with novel agents in 2011: a European perspective.
Heinz Ludwig, Meral Beksac, Joan Bladé, Jamie Cavenagh, Michele Cavo, Martin Kropff

Oncologist· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of relapsed and refractory multiple myeloma in the era of novel agents.
Niels W C J van de Donk, Henk M Lokhorst, Meletios Dimopoulos, Michele Cavo, Gareth Morgan, Martin Kropff

Cancer Treat Rev· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma.
Michel Delforge, Evangelos Terpos, Paul G Richardson, Ofer Shpilberg, Nuriet K Khuageva, Martin Kropff

Eur J Haematol· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.
Philippe Moreau, Halyna Pylypenko, Sebastian Grosicki, Ievgenii Karamanesht, Xavier Leleu, Martin Kropff

Lancet Oncol· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: analysis of the VISTA trial.
Paul Richardson, Rudolf Schlag, Nuriet Khuageva, Meletios Dimopoulos, Ofer Shpilberg, Martin Kropff

Br J Haematol· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study.
Meletios A Dimopoulos, Maria-Victoria Mateos, Paul G Richardson, Rudolf Schlag, Nuriet K Khuageva, Martin Kropff

Eur J Haematol· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone.
Jean-Luc Harousseau, Antonio Palumbo, Paul G Richardson, Rudolf Schlag, Meletios A Dimopoulos, Martin Kropff

Blood· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma.
Monika Engelhardt, Josefina Udi, Martina Kleber, Andrew Spencer, Alberto Rocci, Martin Kropff

Leuk Lymphoma· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues.
Michel Delforge, Joan Bladé, Meletios A Dimopoulos, Thierry Facon, Martin Kropff

Lancet Oncol· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis